Monomethyl Fumarate Brand Name– BAFIERTAM
What is Monomethyl Fumarate
Monomethyl fumarate (MMF) is indicated for the treatment of adults with relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.
Like dimethyl fumarate, MMF exhibits neuroprotective and anti-inflammatory properties; these actions can help delay disability and disease progression.
Monomethyl fumarate is expected to have better gastrointestinal tolerability when compared to dimethyl fumarate.
Monomethyl fumarate received FDA approval in April 2020.
Indications
- multiple sclerosis
For the treatment of relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease
Side Effects
- abdominal pain
- anaphylactoid reactions
- angioedema
- diarrhea
- dyspepsia
- elevated hepatic enzymes
- eosinophilia
- erythema
- flushing
- infection
- leukoencephalopathy
- leukopenia
- lymphopenia
- lymphopenia
- nausea
- progressive multifocal leukoencephalopathy
- proteinuria
- pruritus
- rash
- urticaria
- vomiting
Monitoring Parameters
- CBC with differential
- LFTs
- neurologic function
- serum bilirubin
Contraindications
- breast-feeding
- hepatic disease
- hepatotoxicity
- immunosuppression
- pregnancy
- progressive multifocal leukoencephalopathy
Interactions
- Dimethyl Fumarate
- Diroximel Fumarate
- Ocrelizumab
- Ozanimod
